Plasma kininogen and kininogen fragments are biomarkers of progressive renal decline in type 1 diabetes

Plasma kininogen and kininogen fragments are biomarkers of progressive renal decline in type 1 diabetes

The ability of microalbuminuria to predict early progressive renal function decline in type 1 diabetic patients has been questioned. To resolve this, we determined the plasma proteome differences between microalbuminuric patients with type 1 diabetes and stable renal function (controls) and patients...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Kidney international 2013-06, Vol.83 (6), p.1177-1184
Hauptverfasser: Merchant, Michael L., Niewczas, Monika A., Ficociello, Linda H., Lukenbill, Janice A., Wilkey, Daniel W., Li, Ming, Khundmiri, Syed J., Warram, James H., Krolewski, Andrzej S., Klein, Jon B.
Format: Artikel
Sprache:eng
Schlagworte:
ACE inhibitors
Albuminuria - blood
Albuminuria - etiology
Animals
Biomarkers - blood
Case-Control Studies
Cell Line
Chromatography, Liquid
Diabetes Mellitus, Type 1 - blood
Diabetes Mellitus, Type 1 - complications
Diabetic Nephropathies - blood
Diabetic Nephropathies - etiology
diabetic nephropathy
Disease Progression
Humans
Kidney Tubules, Proximal - metabolism
Kininogen, High-Molecular-Weight - blood
mass spectrometry
Mice
microalbuminuria
Mitogen-Activated Protein Kinase 1 - metabolism
Mitogen-Activated Protein Kinase 3 - metabolism
Molecular Weight
Peptide Fragments - blood
Phosphorylation
Pilot Projects
proteomic analysis
Proteomics - methods
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
Tandem Mass Spectrometry
Time Factors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The ability of microalbuminuria to predict early progressive renal function decline in type 1 diabetic patients has been questioned. To resolve this, we determined the plasma proteome differences between microalbuminuric patients with type 1 diabetes and stable renal function (controls) and patients at risk for early progressive renal function decline (cases) and asked whether these differences have value as surrogate biomarkers. Mass spectrometry was used to analyze small (
ISSN:0085-2538
1523-1755
DOI:10.1038/ki.2013.8